1140 results about "Tumor tissue" patented technology

The invention relates to the technical field of medical image processing, in particular to a multimodal-based digestive tract tumor lesion image segmentation method and segmentation system. The method comprises the following steps: acquiring an alimentary canal tumor lesion image, and extracting an alimentary canal tumor ultrasonic image; evaluating the tumor invasion depth based on the digestive tract tumor ultrasonic image; performing focus three-dimensional visual modeling according to the tumor invasion depth to obtain a digestive tract tumor focus model; extracting a tumor tissue pathological image according to the digestive tract tumor lesion image; performing tumor region segmentation based on the tumor tissue pathological image to obtain digestive tract tumor region data; performing tissue arrangement anomaly detection based on the digestive tract tumor region data to obtain tissue arrangement anomaly data; and calculating a tissue arrangement disorder index according to the tissue arrangement abnormal data and the digestive tract tumor area data. According to the invention, the tumor identification accuracy and the malignant region segmentation precision are improved based on the medical image processing technology.

The invention relates to the technical field of biological medicine, and discloses a pharmaceutical composition of paclitaxel dimer prodrug nanoparticles and a traditional Chinese medicine compound and application of the pharmaceutical composition, and the pharmaceutical composition is composed of Qiyuansanlong prescription freeze-dried powder and paclitaxel dimer prodrug nanoparticles; wherein the paclitaxel dimer prodrug nanoparticles comprise one of NQO1 response type PTX dimer prodrug nanoparticles (PTX-Q-PTX NPs) or GSH (glutathione) response type PTX dimer prodrug nanoparticles (PTX-SeSe-PTXNPs), and the paclitaxel dimer prodrug nanoparticles comprise one of NQO1 response type PTX dimer prodrug nanoparticles (PTX-Q-PTX NPs) and GSH response type PTX dimer prodrug nanoparticles (PTX-SeSe-PTXNPs). According to the pharmaceutical composition disclosed by the invention, a traditional Chinese and western medicine synergistic treatment system is innovatively constructed, and the advantage of multi-dimensional synergistic interaction is shown. Firstly, an NQO1 / GSH double-response type intelligent release system is adopted, and a biomarker highly expressed by tumor tissue can be specifically responded to realize precise drug release, so that the PTX concentration in tumors is improved compared with that of a traditional dosage form, and meanwhile, the drug circulation time is prolonged. Secondly, the active ingredients in the Qiyuansanlong prescription freeze-dried powder can significantly down-regulate the PD-L1 expression level, synergistically enhance CD4 + T and CD8 + T cell infiltration, and form chemical-immune dual killing effects.

A neurosurgery system for probing brain tissue of a patient for tumorous tissue. The system including a suction tool, an excitation source, an optical instrument, and a controller. The suction tool including a suction cannula defining a lumen, an optical fiber configured to transmit fluorescence emitted by the brain tissue; and an indicator configured to selectively emit visible light. An excitation source is configured to emit an excitation light having a wavelength to induce the fluorescence in the tumorous tissue. The optical instrument is coupled to the optical fiber. The optical instrument configured to convert the fluorescence emitted by the brain tissue and transmitted by the optical and configured to determine that the brain tissue is tumorous based on the electrical signal and activate the indicator based on the determination.

Disclosed herein are methods and compositions for preventing or reducing adverse events associated with administration of a RAS(ON) inhibitors. Thus, disclosed are compositions and methods for treating or preventing RAS(ON) inhibitor therapy-associated rash or mucositis. The methods involve administering a compound that binds to cyclophilin A (CypA) to compete with a RAS(ON) inhibitor for CypA binding, thereby reducing tri-complex formation in non-tumor tissues. These approaches may improve the tolerability of RAS(ON) inhibitor therapies without compromising efficacy.

The application provides a novel DNA methylation marker TAGMe-3 for tumor identification and use thereof. The TAGMe-3 gene sequence region has significant methylation difference between cancer tissues and paracancer tissues. As long as abnormal high methylation state of the TAGMe-3 gene sequence region is detected, the subject is determined to belong to a tumor high-risk population. Moreover, the significant difference of the TAGMe-3 presented between tumor tissues and non-tumor tissues exists in different types of tumors (Pan-cancer) in a wide range.

The invention relates to a computer-implemented method for assessing a risk of breast cancer recurrence, to a computer program having instructions which when executed by a computing device or system cause the computer device or system to perform the method as well as to a data-processing system comprising means for carrying out the method for assessing a risk of breast cancer recurrence. The method of the invention is for example performed by whole slide image (WSI) processing, wherein the risk of breast cancer recurrence is assessed from a WSI of a tumor tissue.

The invention discloses an engineered autologous tumor tissue scaffold and application thereof, and the engineered autologous tumor tissue scaffold is prepared by performing specific treatment on autologous tumor tissue to induce immunogenic cell death of the tumor tissue, and then sequentially performing freezing and drying steps; the engineered autologous tumor tissue scaffold can be used for loading dendritic cells and constructing personalized tumor vaccines. According to the stent, autologous tumor tissue is adopted, so that a specific and comprehensive tumor antigen pedigree is reserved, and multi-epitope immunostimulation is provided; and meanwhile, excellent biocompatibility is ensured, the immunological rejection risk is reduced, and relatively high safety is ensured.

The invention discloses organic nano composite hydrogel as well as a preparation method and application of the organic nano composite hydrogel, and belongs to the technical field of biological medicine delivery. The polysaccharide-based nano prodrug in the composite hydrogel can be subjected to surface protonation under the stimulation of a tumor extracellular slightly acidic environment, so that cellular uptake is promoted, low-pH / high-concentration glutathione in tumor cells is responded, intracellular aggregation and controllable release of the nano drug are realized, the retention time of the drug in the cells is prolonged, and the bioavailability of the drug is improved. The technical effect of killing tumor cells through combined chemotherapy is achieved. According to the preparation method disclosed by the invention, the release of the polysaccharide-based nano prodrug from the hydrogel and the tissue infiltration capacity are accelerated by adopting fluorinated orthoester, the infiltration of the polysaccharide-based nano prodrug to cells is increased, and then the drug-loaded compound is encapsulated by using gellan gum, so that the slow-release effect of the polysaccharide-based nano prodrug is enhanced; therefore, the efficient enrichment of the medicine at the tumor part is realized.

The invention provides a tumor living body sampling device, and relates to the field of biological sampling, the tumor living body sampling device comprises: a sampler main body, the sampler main body is a pistol-shaped structure; the inner sampling needle is coaxially and rotatably connected to the inner side of the reversing seat, the inner sampling needle is rotatably connected to the inner side of the sampling outer cylinder, the right cross sections of the sampling outer cylinder and the inner sampling needle are of arch-shaped structures, and the right end parts of the sampling outer cylinder and the inner sampling needle are of needle-shaped spine structures; hollow sampling openings are formed in arch-shaped parts on the right sides of the sampling outer cylinder and the inner sampling needle; the sampling transmission assembly is arranged in the sampler main body, and the sampling operation block drives the sampling outer cylinder and the inner sampling needle to rotate reversely at the same time through the sampling transmission assembly. The tumor tissue is rapidly and completely cut off, tearing damage is avoided, samples are isolated from the tissue, the samples are prevented from being mixed, and the problems that in the existing sampling process, the tissue is difficult to effectively cut off, tissue tearing is easily caused, and tissue samples are not pure are solved.

The invention provides a dual-targeting carrier material, a preparation method thereof and a preparation method of oleanolic acid nanoparticles wrapped by the dual-targeting carrier material, and belongs to the technical field of medicines. The oleanolic acid targeting nanoparticles are prepared by taking a dual-targeting high-molecular copolymer as a carrier material and adopting an emulsification-solvent evaporation method, so that the oleanolic acid can be protected from being quickly degraded, and the in-vivo circulation time of the oleanolic acid can be prolonged. Meanwhile, targeted delivery of oleanolic acid is realized through a targeted group, the concentration of the drug in tumor tissues is improved, and toxic and side effects on normal tissues are reduced. An MTT method is adopted, the inhibition effect of the oleanolic acid nanoparticles on cell growth is researched, and the result shows that the oleanolic acid targeting nanoparticles have a stronger effect of inhibiting tumor cell proliferation compared with an oleanolic acid raw material medicine.

The invention provides application of TRMT61A and its inhibitor tetramethylthiuram disulfide in tumor immunotherapy, and relates to the technical field of biological medicine, clinical research proves that RNA m1A methyltransferase TRMT61A is highly expressed in tumor tissues and is related to poor prognosis of tumor patients, and can be used as one of tumor therapy targets. Meanwhile, high expression of the TRMT61A is related to poor prognosis of a tumor patient receiving anti-PD-1 immunotherapy, and after anti-PD-1 antibody immunotherapy is carried out on the patient with low TRMT61A expression level in the tumor of the patient, pathological complete relief is easier. Tetramethylthiuram disulfide inhibits TRMT61A, inhibits m1A modification regulation of TRMT61A on PD-L1 mRNA, increases PD-L1 protein expression, and is combined with a PD-1 antibody drug to significantly enhance the immunotherapy effect of the anti-PD-1 immune checkpoint drug in treating malignant tumors.

The invention provides an aza-BODIPY molecule with NIR-II fluorescence emission and I-type photodynamic activity and a preparation method thereof. The aza-BODIPY molecule has good light absorption in a near-infrared (NIR) region, the emission peak of the aza-BODIPY molecule is prolonged to a near-infrared second region (NIR-II), and the aza-BODIPY molecule shows an ultrahigh NIR-II fluorescence quantum yield of 13%. Meanwhile, the photosensitizer prepared by adopting aza-BODIPY molecules can effectively generate I-type active oxygen species, namely superoxide anion free radicals, under the excitation of 808nm laser. On the basis, high-resolution tumor fluorescence imaging can be realized by utilizing NIR-II fluorescence of the aza-fluorine boron fluorescent sensitizer, and the aza-fluorine boron fluorescent sensitizer is used for accurate and efficient NIR-II fluorescence imaging mediated I-type photodynamic therapy of deep tumor tissues.

The invention relates to the technical field of biopsy puncture, and discloses a tumor biopsy puncture device for biopsy sampling, the tumor biopsy puncture device comprises an outer needle assembly and an inner needle assembly, the outer needle assembly comprises a needle base and an outer needle tube fixed with the needle base, the inner needle assembly comprises a needle cylinder and an inner needle core slidably arranged in the needle cylinder, a needle cavity is arranged at the needle tip end of the inner needle core, and the needle cavity is communicated with the needle base. An ejection mechanism is arranged in the needle cylinder, the ejection mechanism is used for triggering the inner needle core to eject outwards in the length direction of the outer needle tube, and the ejection mechanism comprises a connecting part fixed to the inner needle core, a locking piece arranged on the connecting part and used for limiting the position of the inner needle core and a pull rod fixed to the connecting part and capable of penetrating out of the needle cylinder in a sliding mode. According to the tumor biopsy puncture equipment for biopsy sampling, by arranging the ejection mechanism, compared with an existing manual operation mode, the ejection force of the inner needle core is adjusted by changing the stretching or compression degree of the elastic component, and the cutting requirements of tumor tissues of different textures can be met.

The invention provides application of lactic acid modified histone H3 in preparation of drugs and / or diagnostic kits for preventing and / or treating pancreatic ductal adenocarcinoma, and belongs to the technical field of disease diagnosis and / or treatment. The invention provides application of a lactic acid modified histone H3 as a target spot in preparation of a pancreatic ductal adenocarcinoma diagnostic kit or a medicine for preventing and / or treating pancreatic ductal adenocarcinoma. The site of lactic acid modification is 23-site lysine. The expression of H3K23la detected in clinical sample tissues in pancreatic ductal adenocarcinoma tumor tissues is obviously higher than that in para-carcinoma normal tissues, overexpression and non-expression of H3K23la in cells are regulated and controlled through in-vitro experiments in combination with overexpression and knock-down technologies, and results show that proliferation, invasion and migration capacities of pancreatic ductal adenocarcinoma cells are remarkably inhibited, so that the pancreatic ductal adenocarcinoma cells are remarkably inhibited. Therefore, the H3K23la can be used as a target spot for diagnosis and treatment of the pancreatic duct adenocarcinoma, and has wide application in diagnosis or treatment of the pancreatic duct adenocarcinoma.

The invention discloses a Claudin18.2-targeting nano antibody and application thereof, and belongs to the technical field of molecular biology. Aiming at the unique advantages of a nano antibody in the prior art, the invention provides a nano antibody targeting Claudin18.2, the amino acid sequence of the targeting nano antibody is shown as SEQ ID NO.1, and the nano antibody has relatively strong affinity with Claudin18.2 positive cells 293T-Claudin18.2, and can be combined with Claudin18.2 protein expressed on the surfaces of the cells. The targeted Claudin18.2 nano antibody provided by the invention can be prepared through in-vitro engineering bacterium mass expression, can be applied to preparation of protein detection antibodies or therapeutic antibodies, can be used for in-vivo and in-vitro detection of tumor tissues expressed by Claudin18.2, and has important commercial value in clinical disease diagnosis and treatment.

The invention discloses a multi-modal tumor identification method based on a frequency domain attention mechanism. The method comprises the following steps: S1, acquiring multi-frequency bioelectrical impedance signals of tumor tissues and normal tissues and corresponding medical tumor pathological images; s2, extracting a frequency-time feature of the electrical impedance signal and a spatial feature of the pathological image through a multi-modal feature coding module, and generating a multi-modal fusion feature; s3, converting the multi-modal fusion features into frequency domain representation, performing weighted enhancement on the multi-modal fusion features through a frequency domain attention module, and outputting the features; and S4, fusing the features output by the frequency domain attention module and the superficial layer features in the coding stage through jump connection to obtain enhanced features, inputting the enhanced features into a decoding network, and outputting a tumor classification result. According to the method, the bioelectrical impedance signal and the multi-modal information of the pathological image are fused, and a frequency domain attention mechanism is introduced to effectively improve the expression ability of key frequency characteristics.

The invention relates to the technical field of nano-drug presentation systems, in particular to a TCR (T cell receptor) nano-vesicle antibody with both T cell redirection and immunosuppression reversal as well as a preparation method and application of the TCR nano-vesicle antibody. The TCR nano-vesicle antibody comprises a vesicle formed by a liposome and a cell membrane; tCR protein, a PD-1 antibody and a CD3 antibody are loaded on the vesicles. The nano vesicle antibody has the functions of T cell redirection and immunosuppression reversion; the difficulty of low stability of the soluble TCR is overcome; the polypeptide can be rapidly enriched in tumor tissues through tumor specificity TCR, and CD8 + T cells infiltrated by tumors are directly activated through an anti-CD3 antibody; depletion of T cells can be reversed through the PD-1 antibody on the surface, and the effector function of tumor infiltration CD8 + T cells is improved. The technical scheme can solve the technical problems that the TCR stability is not ideal and the immunosuppression state of the tumor microenvironment is difficult to overcome, and has ideal application and popularization prospects.

The invention belongs to the field of biological medicine, and relates to an engineered cell membrane nano-vesicle as well as a preparation method and application thereof. The invention provides application of normal fibroblasts in preparation of drugs for treating tumors or tumor diagnostic reagents or nano drug delivery systems or engineered vesicles. The vesicles prepared from the normal fibroblasts have high specificity and capability of rapidly targeting multiple types of tumor tissues, can realize tumor targeted diagnosis imaging or drug delivery, greatly reduce accumulation in normal organs and non-targeted tissues, maximally weaken toxic and side effects of the vesicles in vivo, and have good application prospects. And the safety and the effectiveness are greatly improved.

The invention relates to the field of biomedical treatment, and particularly discloses application of CD146 in diagnosis and treatment of rhabdomyosarcoma, and the CD146 is specifically and highly expressed in tumor tissues of the rhabdomyosarcoma. The invention provides application of a biomarker for diagnosing rhabdomyosarcoma or / and a detection reagent thereof in preparation of a product for diagnosing rhabdomyosarcoma. Meanwhile, experiments prove that the CD146-targeted chimeric antigen receptor T cell has a relatively strong tumor cell killing effect and can effectively remove CD146 positive tumor cells. The CD146 biomarker provided by the invention provides a new target and theoretical basis for early diagnosis and individualized treatment of rhabdomyosarcoma, and has important clinical application value.

The invention discloses a high-specificity minimal residual disease (MRD) monitoring method and system based on circulating tumor DNA (ctDNA). The method comprises the following steps: receiving tumor tissue sequencing data of an UTUC patient, and generating a double-Panel target list containing personalized and fixed Panel; respectively extracting plasma cfDNA and leukocyte gDNA; performing vacuum concentration, hybrid capture and sequencing on the cfDNA library by using the double Panel lists, and performing deep sequencing on the leukocyte gDNA; constructing an individualized clonal hematopoietic mutation filtering database; actively filtering and rejecting clonal hematopoietic background mutation by utilizing a filtering database; and calculating an MRD load score based on the filtered tumor-derived mutation and outputting a report. The system comprises corresponding modules which are used for automatically executing the process. According to the invention, through cooperation of four major technologies of double-Panel design, process optimization, UMI error correction and active clonal hematopoietic filtration, MRD monitoring with extremely high sensitivity and specificity on UTUC is realized, false positive is significantly reduced, and the kit has drug resistance early warning potential.

The invention discloses a manganese-enriched albumin boron-containing nano preparation as well as a preparation method and application thereof, and belongs to the field of medicines and nano biological materials. According to the manganese-enriched albumin boron-containing nano preparation, albumin serves as a core carrier, phenylboronic acid derivatives are loaded through covalent or electrostatic interaction, then a manganese oxide layer is deposited on the surface in situ, and the prepared manganese-enriched albumin boron-containing nano preparation can remarkably increase the boron accumulation amount in tumor tissue; local and systemic immune response of tumors is promoted through the immune activation effect of manganese ions, so that the treatment effect of boron neutron capture therapy (BNCT) is remarkably improved. According to the invention, a phenylboronic acid derivative with tumor targeting is compounded with albumin, and manganese oxide is deposited in situ on the surface of the phenylboronic acid derivative, so that a multifunctional nano preparation with high boron delivery efficiency, immunological enhancement and magnetic resonance imaging functions is formed.

The invention belongs to the technical field of biological medicines, and particularly discloses a bionic nano-vesicle for regulating and controlling neutrophil phenotype in combination with ultrasound, and a preparation method and application of the bionic nano-vesicle. The bionic nano-vesicle provided by the invention can be broken under the action of high-concentration glutathione existing in a tumor tissue microenvironment to release the sound-sensitive agent and functional siRNA, and under the action of US irradiation, the sound-sensitive agent is activated to generate a large amount of ROS, promote tumor cell DNA breakage, generate a large amount of double-stranded DNA, activate APC and promote IFN-beta release, so that the tumor tissue microenvironment is inhibited. The released functional siRNA can promote the N2-type neutrophile granulocyte to become N1-type neutrophile granulocyte, and the released functional siRNA can prevent the N1-type neutrophile granulocyte from being reversed to the N2-type neutrophile granulocyte again, so that the regulation and control on the phenotype of the neutrophile granulocyte are realized; under catalysis of CAT rich in the thylakoid membrane, H2O2 overexpressed by tumor tissue is decomposed into oxygen, the tumor hypoxia microenvironment can be relieved, and the tumor treatment effect can be improved.

The invention provides an engineered bacterium outer vesicle drug delivery system capable of efficiently penetrating a blood brain barrier and targeting glioblastoma as well as a preparation method and application of the engineered bacterium outer vesicle drug delivery system, and belongs to the field of drug delivery. The engineering bacteria outer vesicle drug delivery system comprises double-layer phospholipid layer vesicles BEVs, a drug delivery system and a drug delivery system, wherein the particle size of the double-layer phospholipid layer vesicles BEVs is 20 The anti-tumor drug is wrapped in the BEVs, the surface of the BEVs is modified with functional polypeptide, and the functional polypeptide is at least one of Angiopep-2 and TAT cell penetrating peptide. Animal experiments verify that the synergistic effect of the Angiopep-2 and the TAT peptide can overcome the problem of modification saturation of the Angiopep-2 peptide, and significantly improve the ability of BEVs to penetrate through BBB and target tumor tissues. Therefore, the BEVs modified by the Angiopep-2 peptide and the TAT peptide have the advantages of multi-stage targeting, high efficiency and synergy, and can effectively deliver chemotherapeutic drugs to tumor tissues.

The invention relates to the field of biology, and provides a human immortalized pancreatic cancer fibroblast as well as a preparation method and application thereof.The human immortalized pancreatic cancer fibroblast comprises three cell strains which are all primary fibroblast cells extracted from tumor tissues of pancreatic ductal adenocarcinoma patients, the human pancreatic cancer fibroblast cell strain CAFPC-2209131, the human pancreatic cancer fibroblast cell strain CAFPC-2209132 and the human pancreatic cancer fibroblast cell strain CAFPC-2303221 are classified and named as the human pancreatic cancer fibroblast cell strain CAFPC-2209131, the human pancreatic cancer fibroblast cell strain CAFPC-2209132 and the human pancreatic cancer fibroblast cell strain CAFPC-2303221 respectively, the human pancreatic cancer fibroblast cell strain CAFPC-2209132 and the human pancreatic cancer fibroblast cell strain CAFPC-2303221 are all Cell STR identification and immunofluorescence detection prove that the cell strain is a fibroblast cell strain. After the tumor-associated fibroblast and pancreatic cancer cells are co-cultured, the proliferation ability of the tumor cells is obviously enhanced, and the sensitivity of the tumor cells to a chemotherapeutic drug gemcitabine is reduced. A new thought is provided for diagnosis and treatment of pancreatic cancer, and based on the pancreatic cancer in-vitro co-culture model established in vitro, the application has important significance for researching the effect and related mechanisms of fibroblasts in the pancreatic cancer tumor microenvironment.

Handheld surgical systems having an adjustable, ergonomic handheld controller and a series of interchangeable surgical instruments with dexterous, end-effectors for performing a surgical procedure, e.g., removing brain tumor tissue from confined spaces, and methods of use thereof are disclosed. The end-effector may be actuated in one or more degrees of freedom via a tendon routing system comprising a plurality of antagonistic pairs of tendons extending from the end-effector to a plurality of independently rotatable capstan shafts disposed within a housing of the interchangeable instrument and configured to be releasably and operatively coupled to one or more motors disposed within the handheld controller.

The invention discloses a multifunctional hydrogel patch and a preparation method and application thereof.The biological patch comprises decellularized freeze-dried tumor tissue (dFCT) and a hydrogel layer loaded with hair melanin nanoparticles (HNPs), the dFCT is obtained by decellularizing and freeze-drying the tumor tissue, and rich natural extracellular matrix components are reserved; hNPs is extracted from hair and has excellent active oxygen scavenging capacity and photothermal conversion performance; it is preferable that the hydrogel layer is a methacrylated gelatin (GelMA). The patch disclosed by the invention shows a remarkable cell viability promoting effect and antibacterial ability in vitro, and can accelerate wound healing by reducing oxidative stress, inhibiting inflammatory response and promoting angiogenesis in vivo. The patch is simple and convenient in preparation process and natural in component source, has multiple functions of resisting bacteria, resisting oxidation, promoting tissue regeneration and the like, and is suitable for wound repair treatment.

The utility model relates to the technical field of biological chips, in particular to a multi-tissue co-culture organoid chip which comprises a chip main body, and a plurality of culture hole groups are formed in the chip main body; the culture hole group comprises a first cell culture hole and at least one second cell culture hole communicated with the first cell culture hole, and a porous membrane for cells to pass through is arranged at the communicated part of the first cell culture hole and each second cell culture hole; the mode that the two cell culture holes are communicated and separated through the porous membrane is adopted, organoid co-culture is achieved, meanwhile, the pathological and physiological dynamic microenvironment of tumor tissue can be simulated, the operation process of medicine screening is simplified, and the medicine screening efficiency is greatly improved.

The invention relates to the technical field of compound preparation and medicine, in particular to a boron atom-labeled compound for targeting fibroblast activating protein as well as a preparation method and application of the boron atom-labeled compound. The preparation method comprises the following steps: carrying out acid amine condensation on (4-(((2, 5-dioxopyrrolidine-1-yl) oxy) carbonyl) phenyl) boric acid and an FAP targeting ligand to obtain a boron atom-labeled compound targeting the fibroblast activating protein; and the FAP targeting ligand is FAPI-46 or FAP-2286 (Fibroblast Amplified Polymorphism). The compound is easy to prepare, high in purity and good in stability, the content of boron atoms in tumor tissue can be greatly increased, and a treatment basis is provided for boron neutron capture therapy.

The invention discloses application of a tumor-derived acellular extracellular matrix in preparation of a medicine for promoting angiogenesis and tissue regeneration. The invention provides a strategy for regulating and controlling tissue regeneration based on a tumor-derived acellular extracellular matrix microenvironment, a novel angiogenesis promoting biological material is constructed by combining the high similarity of a tumor microenvironment and a regeneration microenvironment such as angiogenesis, and high-efficiency regeneration is realized in various tissue defects. In addition, due to the characteristic of rapid proliferation of the tumor tissue, the productivity bottleneck of a traditional acellular extracellular matrix raw material source is broken through, and sustainable biological raw materials are provided for large-scale production. The method successfully solves the problem that a specific tissue-derived acellular extracellular matrix is difficult to regenerate in a complex damaged microenvironment.

The invention discloses a modular tumor microenvironment response polypeptide and a preparation method and application thereof. The modular tumor microenvironment response polypeptide is composed of the following functional modules: a targeting and chemotactic module used for targeting tumor cell surface p32 protein and tumor lymphatic vessels and promoting tumor tissue penetration and enrichment; the microenvironment double-response module is used for being cut by MMP-2 / 9 enzyme and broken by high-concentration glutathione GSH in a tumor microenvironment to trigger self-assembly; the self-assembly driving module is used for exposing after the microenvironment responds to activation and driving short peptides to be self-assembled to form a nano structure; a killing module: a pro-apoptotic peptide PAD used for targeting a mitochondrial membrane and inducing tumor cell apoptosis; and the stability optimization module is used for enhancing the degradation resistance of the oligopeptide. By integrating targeted delivery, enzyme digestion response, acid-sensitive release and stabilizing structures, the problems of insufficient targeting property, inaccurate release, poor stability, diagnosis-treatment splitting and the like of the anti-tumor drug and the developing agent are solved.